Investigational drug · Phase 2
ATX-01
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Myotonic Dystrophy 1.
Phase 2Last checked: Nov 19, 2026Latest source record: Feb 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "ATX-01"
First trial start
2024
Oct 15, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ATX-01", any sponsor or status.
Conditions studied
As listed on its trial records.
- Myotonic Dystrophy 1
Approved drugs for the same conditions: Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "ATX-01" as an intervention, largest first.
- Efficacy and Safety of ATX01 in Adult Patients With CIPN (Chemotherapy-induced Peripheral Neuropathy)Pivotal-lookingActive, not recruiting
AlgoTherapeutixIndustry
NCT05593614 · 276 participants · Start Feb 28, 2023 · Primary completion Sep 2024
Drug: ATX01 10%; ATX01 15% and 1 more · For: Chemotherapy-induced Peripheral Neuropathy
Sites: Clermont, Florida; Miami, Florida; Port Charlotte, Florida · 43 sites in all
- Study of ATX-01 in Participants With DM1Recruiting
ARTHEx Biotech S.L.Industry
NCT06300307 · 56 participants (planned) · Start Oct 15, 2024 · Primary completion Jul 2027
Drug: ATX-01; Placebo · For: Myotonic Dystrophy 1
Sites: Los Angeles, California; Gainesville, Florida; Iowa City, Iowa · 12 sites in all
AlgoTherapeutixIndustry
NCT05917912 · 14 participants · Start Jun 14, 2023 · Primary completion Feb 29, 2024
Drug: Amitriptyline Hydrochloride; Placebo · For: Erythromelalgia
Sites: Rochester, Minnesota; Erlangen, Germany
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Myotonic Dystrophy 1
- Del-desiranAOC 1001Phase 33 trials
Avidity Biosciences, Inc. · DM1, Myotonic Dystrophy, Myotonic Dystrophy 1
- PGN-EDODM1Phase 22 trials
PepGen Inc · Myotonic Dystrophy 1
- SRP-1003ARO-DM1Phase 21 trial
Sarepta Therapeutics, Inc. · Myotonic Dystrophy 1
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.